2019年12月18日 · The TULIP-2 trial showed that anifrolumab (at a dose of 300 mg administered intravenously every 4 weeks) in patients with active SLE was superior to placebo in the achievement of composite end ...

Here, we report the primary analysis results of the phase II TULIP-LN trial, which explored the safety and efficacy of two anifrolumab dosing regimens alongside standard therapy in patients with active LN.

2023年8月23日 · Objective: To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP)-LN trial (NCT02547922) of 2 anifrolumab dosing regimens versus placebo.

Here, we report the primary analysis results of the phase II TULIP-LN trial, which explored the safety and efficacy of two anifrolumab dosing regimens alongside standard therapy in patients with active LN.

2020年3月11日 · The primary outcome of the first year of the phase II TULIP-LN randomised, placebo-controlled trial suggested that an intensified regimen (IR) of anifrolumab has potential to be a novel treatment option for patients with active LN.

We’re going to be discussing the two articles reporting results from the TULIP–1 and TULIP–2 trials, which looked at the use of the type I interferon receptor blocker anifrolumab in systemic lupus erythematosis.

2023年8月22日 · Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the...

2024年11月1日 · It is noteworthy that in the phase III studies (TULIP-1 and TULIP-2), patients with active severe LN or neuropsychiatric SLE were excluded. 12,17 An elevated type I IFNGS has been proven to be present in > 80% of patients with LN and is associated with active renal disease and risk of treatment failure. 18,19 In the phase II TULIP-LN study ...

2019年9月3日 · What is the TULIP 2 Trial? TULIP stands for “Treatment of Uncontrolled Lupus via the Interferon Pathway.” It was the second of the two scheduled phase III trials for anifrolumab. TULIP 2 was designed after assessing the …

In TULIP-2, 362 SLE patients were randomized to blindly receive 300 mg anifrolumab or placebo intravenously every 4 weeks for 48 weeks. Inclusion criteria were based on a SLEDAI score ≥ 6, with at least 4 clinical SLEDAI points.